Telix Pharmaceuticals has established Telix Manufacturing Solutions (TMS) in Yokohama, Japan, marking its first cyclotron facility in the Asia-Pacific (APAC) region.  The move is part of Telix’s global strategy to strengthen its radiopharmaceutical manufacturing footprint and enables greater control of both clinical and commercial supply. 

The facility, originally set up in 2018 by JFE Engineering, was designed with a cyclotron and specialized hot cells  structures critical for producing diagnostic isotopes like zirconium-89.  Telix now plans to take over management and operate it for its key products, including TLX250-CDx (Zircaix®) in renal imaging, future prostate cancer tracers (68Ga-PSMA), and 18F-based agents. 

In addition, Telix intends to install its proprietary ARTMS QUANTM Irradiation System (QIS®) cyclotron technology at the Yokohama site, aiming to standardize and scale up the production of critical medical isotopes more efficiently. This boost in capacity is especially strategic: Japan is globally recognized as the second-largest nuclear medicine market, and having a local, in-house production base strengthens Telix’s ability to serve it effectively. 

From a business standpoint, this expansion could help Telix reduce reliance on partners for isotope supply, manage costs better, and bring production closer to demand centers in the region. The TMS Yokohama facility will also support Telix’s future R&D and manufacturing for its broader radiopharmaceutical pipeline.